SciELO - Scientific Electronic Library Online

 
vol.6 número17Assistência de enfermagem humanizada para pacientes safenectomizadosMonkeypox, escopo do que é conhecido índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Não possue artigos similaresSimilares em SciELO

Compartilhar


Vive Revista de Salud

versão impressa ISSN 2664-3243

Resumo

MALDONADO, Paola Alexandra Cárdenas; AGUINSACA, Karina Fernanda Pucha  e  COELLO, Mariela de los Ángeles Cárdenas. Efficacy and safety of SARS-CoV-2 vaccines in patients with autoimmune rheumatologic diseases. Vive Rev. Salud [online]. 2023, vol.6, n.17, pp.547-559.  Epub 08-Maio-2023. ISSN 2664-3243.  https://doi.org/10.33996/revistavive.v6i17.245.

Patients with autoimmune rheumatologic diseases have a higher risk of infection by SARS-CoV-2 due to factors inherent to the disease, as well as those derived from treatment. With the development of vaccines, immunization has been prioritized in this group of patients; however, the efficacy and safety of vaccines against SARS-CoV-2 has not been studied in this population due to their exclusion in phase II-III clinical trials. Objective. to analyze the efficacy and safety of vaccines against SARS-CoV-2 in patients with autoimmune rheumatologic diseases. Methodology. A systematic review was performed, using the PRISMA statement, as search criteria were considered Portuguese, English and Spanish publications, related to the efficacy and safety of vaccines against SARS-CoV-2 during the last 6 years. The search for articles was developed in databases such as PubMed, Scopus and ScienceDirect published in English, Portuguese and Spanish published during the last 6 years to date. Results. A total of 79 articles were found, 27 in PubMed, 52 in Google Scholar; the number was reduced to 60, eliminating 19 for duplicity, 27 for article ABSTRACT, after an exhaustive analysis of the content of the information to obtain a total of 8 articles for the analysis of the study. Conclusion. The efficacy of vaccines against SARS-CoV-2 in patients with rheumatologic diseases is reduced, attributed to the use of glucocorticoids and immunosuppressive therapies in which rituximab, mycophenolate mofetil and methotrexate stand out, while safety based on adverse effects is similar to those found in the general population.

Palavras-chave : Rheumatic diseases; Coronavirus infections; Immunogenicity, Vaccine; Vaccines.

        · resumo em Português | Espanhol     · texto em Espanhol     · Espanhol ( pdf )